ILiAD is a clinical-stage biotechnology company developing the BPZE1 live attenuated vaccine to prevent and treat diseases caused by Bordetella pertussis, which leads to approximately 200,000 deaths and 16 million cases globally each year. The company's approach targets both the prevention of colonization and transmission of the bacteria, addressing a critical gap in current vaccination strategies.
Funding
$42.8M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
KPFounders
Product
Problem
Pertussis, caused by the Bordetella pertussis bacteria, results in significant global morbidity and mortality, with approximately 200,000 deaths and 16 million cases annually. Current vaccination strategies primarily focus on disease prevention but do not effectively prevent bacterial colonization and transmission, leaving a critical gap in controlling the spread of pertussis.
Solution
ILiAD Biotechnologies is developing BPZE1, a live attenuated vaccine, to prevent and treat diseases caused by Bordetella pertussis. The BPZE1 vaccine targets both the prevention of colonization and transmission of the bacteria, addressing a critical gap in current vaccination strategies. By preventing colonization, the vaccine aims to reduce the spread of the bacteria within communities, offering a more comprehensive approach to pertussis control. The live attenuated nature of the vaccine is intended to stimulate a robust and long-lasting immune response, providing enhanced protection against pertussis.
Target Audience
The primary target audience includes infants, children, adolescents, and adults at risk of pertussis infection, as well as public health organizations seeking to control the spread of the disease.
Features
- Live attenuated vaccine designed to elicit a broad immune response.
- Targets both prevention of disease and reduction of bacterial transmission.
- Designed to prevent colonization of Bordetella pertussis.